Pfizer-BioNTech potential COVID-19 vaccine shows promise in additional data
By Reuters Staff REUTERS - German biotech firm BioNTech and U.S. drugmaker Pfizer on Monday reported additional data from their experimental COVID-19 vaccine that showed it was safe and induced an immune response in patients
By Reuters Staff
REUTERS - German biotech firm BioNTech and U.S. drugmaker Pfizer on Monday reported additional data from their experimental COVID-19 vaccine that showed it was safe and induced an immune response in patients.
The companies said the data also demonstrated an induction of high level of T-cell responses against the novel coronavirus.
More than 150 possible vaccines are being developed and tested around the world to try to stop the pandemic. There are 23 candidates in human clinical trials, including from Moderna and AstraZeneca Plc.
Experts have cautioned a safe and effective vaccine will take 12-18 months to develop.
The results were disclosed from a trial in Germany testing 60 healthy volunteers, and come after the companies earlier this month reported data from a corresponding early-stage trial in the United States.
The trial showed that volunteers given two doses of the vaccine produced virus-neutralizing antibodies, similar to the U.S. trial.
The data is available on an online preprint server at medrxiv and is undergoing scientific peer-review for potential publication, the companies said.
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
SHANGHAI (Reuters) - Tesla is planning to export Model 3 vehicles made in China to Asian and European markets, two sources familiar with the matter told Reuters on Friday. The U.S.
By Lucia Mutikani WASHINGTON (Reuters) - U.S. consumer prices rose solidly in August, with the cost of used cars and trucks accelerating by the most in more than 51 years likely as Americans shunned public transportation because of fears of contracting COVID-19
By Tanishaa Nadkar and Pushkala Aripaka (Reuters) - Life and general insurer Aviva is offloading its Singapore business to a consortium led by Singapore Life, for S$2.7 billion ($1.98 billion), as the London-listed firm sharpens its focus on Britain, Ireland and Canada.